Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Return on Invested Capital: 2024-2025

Historic Return on Invested Capital for Entrada Therapeutics (TRDA) over the last 1 years, with Sep 2025 value amounting to -0.33%.

  • Entrada Therapeutics' Return on Invested Capital fell 43.00% to -0.33% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.33%, marking a year-over-year decrease of 43.00%. This contributed to the annual value of 0.14% for FY2024, which is N/A change from last year.
  • Latest data reveals that Entrada Therapeutics reported Return on Invested Capital of -0.33% as of Q3 2025, which was down 37.36% from -0.24% recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Return on Invested Capital registered a high of 0.25% during Q2 2024, and its lowest value of -0.33% during Q3 2025.
  • Moreover, its 2-year median value for Return on Invested Capital was 0.08% (2024), whereas its average is -0.01%.
  • Data for Entrada Therapeutics' Return on Invested Capital shows a maximum YoY plummeted of 49bps (in 2025) over the last 5 years.
  • Over the past 2 years, Entrada Therapeutics' Return on Invested Capital (Quarterly) stood at 0.11% in 2024, then slumped by 43bps to -0.33% in 2025.
  • Its Return on Invested Capital was -0.33% in Q3 2025, compared to -0.24% in Q2 2025 and 0.11% in Q4 2024.